Trials / Completed
CompletedNCT00651560
Vytorin As Strategy To Reduce Dislipidemia In Adults (0653A-148)
Vytorin As Strategy To Reduce Dislipidemia In Adults
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 167 (actual)
- Sponsor
- Organon and Co · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is intended to allow physicians to check the superior clinical efficacy of Vytorin compared to atorvastatin, as the most adequate therapy using the ATP-III goals achievement and cardiovascular risk reduction in adult patients with dislipidemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ezetimibe (+) simvastatin | ezetimibe 10mg (+) simvastatin 20 mg once daily for 4 weeks of treatment. |
Timeline
- Start date
- 2005-11-01
- Primary completion
- 2005-12-23
- Completion
- 2005-12-23
- First posted
- 2008-04-03
- Last updated
- 2024-08-15
Source: ClinicalTrials.gov record NCT00651560. Inclusion in this directory is not an endorsement.